OC
OREX

Oppenheimer & Co’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Oppenheimer & Co’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-5,612
Closed -$118K – 1462
2015
Q3 		$118K Buy
5,612
+2,000
+55% +$68.5K ﹤0.01% 1249
2015
Q2 		$179K Buy
+3,612
New +$216K 0.01% 1330
2014
Q1 		– Sell
-9,420
Closed -$530K – 1557
2013
Q4 		$530K Buy
+9,420
New +$529K 0.02% 792

Other funds holding OREX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Oppenheimer & Co's OREX Position: Q4 2015 in Review

Oppenheimer & Co sold out of Orexigen Therapeutics, Inc. (OREX) in Q4 2015, closing a stake of 5,612 shares — an estimated $118K sold.

Oppenheimer & Co first reported a position in OREX in Q4 2013 and held it in 3 quarters. The position peaked at $530K in Q4 2013. 121 funds tracked by Wall St. Rank hold OREX as of Q4 2015.

  • Oppenheimer & Co reported no remaining Orexigen Therapeutics, Inc. position as of Q4 2015 after selling out during the quarter.
  • Oppenheimer & Co sold 5,612 Orexigen Therapeutics, Inc. shares in Q4 2015, an estimated $118K.
  • Oppenheimer & Co first reported a position in Orexigen Therapeutics, Inc. in Q4 2013 and held it in 3 quarters.
  • Oppenheimer & Co's Orexigen Therapeutics, Inc. position peaked at $530K in Q4 2013.
  • 121 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q4 2015.

Based on Oppenheimer & Co's 13F filing for Q4 2015, filed 3 Feb 2016.